Sanuwave Health Inc (SNWV) 0.6800 $SNWV
SANUWAVE Health to Hold 2013 Financial Results and Business Update Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Wed Mar 26, 7:30AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the Company will release financial results for the year ended December 31, 2013 after the markets close on March 31, 2014.
SANUWAVE raises gross proceeds of USD10.1m from private placement
M2 - Wed Mar 19, 8:28AM CDT
Regenerative medicine company SANUWAVE Health (OTC BB:SNWV) stated on Tuesday that it has raised gross proceeds of USD10.1m from a private placement led by RA Capital Management.
SANUWAVE Closes $10.1M Private Placement Led by RA Capital Management
GlobeNewswire - Tue Mar 18, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced it has closed a private placement with institutional and select accredited investors raising total gross proceeds of $10.1 million. The financing was led by established life-sciences investor RA Capital Management, LLC, a Boston-based healthcare crossover fund that invests in development-stage private and public drug, medical device, and diagnostic companies and also included existing shareholders. Included in the total is the conversion into equity, under the same terms as the private placement, of $815,000 of convertible notes with existing shareholders, including a member of the management team.
SANUWAVE Announces Agreement for Licensing and Distribution for Gulf Cooperation Council (GCC) Region
GlobeNewswire - Tue Feb 11, 7:30AM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that it has signed an agreement with Wirthlin, a Dentons Innovation Group Partnership (Wirthlin-Dentons), to provide strategic advisory services and to establish a joint venture company that will license its dermaPACE device and create a sales and distribution system for the GCC - defined as the Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Qatar, and Bahrain. The joint venture arrangement expects to have a legal and organizational structure in place in the second quarter of 2014, which enables rollout of SANUWAVE's dermaPACE device in the fourth quarter.
SANUWAVE Provides Update on Patient Enrollment - Over 75% Now Enrolled in Pivotal dermaPACE Clinical Trial
GlobeNewswire - Wed Jan 29, 7:30AM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that it has enrolled over seventy-five percent (75%) of the minimum required patients in the Phase III supplemental clinical trial evaluating the dermaPACE device on patients with diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients; which is on track to occur in the first quarter of 2014.
SANUWAVE Reports Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 7:30AM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported financial results for the three and nine months ended September 30, 2013 and provided a business update. The Company will host a conference call today at 10:00 a.m. Eastern Time.
SANUWAVE to Hold Third Quarter Financial Results Conference Call on Tuesday, November 12
GlobeNewswire - Thu Nov 07, 3:30PM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that the Company will release financial results for the third quarter ended September 30, 2013 prior to the opening of the market on Tuesday, November 12, 2013. The Company will host a conference call on Tuesday, November 12, 2013 at 10:00 a.m. Eastern Time.
SANUWAVE Receives U.S. Patent for New Type of Applicators Used for Shock Wave Technology
GlobeNewswire - Thu Oct 17, 7:31AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled "Extracorporeal Shock Wave Device." The claims of the patent (patent number 8,556,813) relate to a new extracorporeal applicator, which creates significant advantages for certain applications. The patent has a term extending to April 2031.
SANUWAVE Provides Update on Patient Enrollment in Pivotal dermaPACE Clinical Trial
GlobeNewswire - Tue Oct 08, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that it has enrolled fifty percent (50%) of the minimum required patients in the Phase III supplemental clinical trial evaluating the dermaPACE device on patients with diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients and is on-track for completion in the first quarter of 2014.
SANUWAVE's orthoPACE Medical Device Receives Regulatory Approval in South Korea
GlobeNewswire - Tue Sep 10, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that its orthoPACE device has received official regulatory approval from the South Korean Ministry of Food and Drug Safety (MFDS - South Korea). With this approval, SANUWAVE will begin commercializing orthoPACE in South Korea. The orthoPACE device has been proven safe and effective for the treatment of chronic tendonitis and joint pain in the musculoskeletal system. orthoPACE treatments have been especially effective in treating plantar fasciitis and tendonitis, which commonly require surgery.
OTC Signal Daily Stock Watch - SANUWAVE Health, Inc. (OTCQB: SNWV)
WorldStockWire - Mon Sep 09, 1:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
SANUWAVE Appoints Life Sciences Industry Executive, Alan L. Rubino To Its Board
GlobeNewswire - Wed Sep 04, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced the appointment of Alan L. Rubino to the Company's Board of Directors. Mr. Rubino has more than 30 years of experience at every level of the biopharmaceutical industry, including positions focused on sales and marketing and SEC matters. With this appointment, the Company's Board has four members.
SANUWAVE Reports Second Quarter 2013 Financial Results
GlobeNewswire - Wed Aug 14, 3:30PM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported financial results for the three and six months ended June 30, 2013 and provided a business update. The Company will host a conference call on Thursday, August 15 at 10:00 a.m. Eastern Time.
SANUWAVE to Hold Second Quarter Financial Results Conference Call on Thursday, August 15
GlobeNewswire - Tue Aug 13, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that the Company will release financial results for the second quarter ended June 30, 2013 following the close of the market on Wednesday, August 14, 2013. The Company will hold a conference call on Thursday, August 15 beginning at 10:00 a.m. Eastern time to discuss the second quarter financial results and provide a business update.
SANUWAVE Announces Conversion of All Senior Secured Notes
GlobeNewswire - Mon Aug 05, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that all of the holders of the Company's 18% senior secured convertible promissory notes voluntarily converted all of the outstanding principal and interest of the notes into common stock on July 31, 2013. SANUWAVE had entered into subscription agreements between November 2012 and February 2013 with select accredited investors, most of whom had invested in the Company's previous financing rounds, and issued the aggregate $2.0 million notes in March 2013.
SANUWAVE Health Inc concludes USD1.6m units in public offering
M2 - Fri Jul 26, 6:58AM CDT
Shockwave technology company SANUWAVE Health Inc (OTC BB:SNWV) revealed on Thursday the sale of approximately USD1.6m units in a public offerings at USD0.55 per unit, each unit consist of one share of common stock and a warrant to purchase one-half share of common stock.
SANUWAVE Closes Public Offering
GlobeNewswire - Thu Jul 25, 10:15AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) announced today that it has sold approximately $1.6 million in Units, with each Unit consisting of one share of common stock and a warrant to purchase one-half share of common stock, in a public offering which closed today. The price per Unit is $0.55. The approximately 2.9 million Units separated immediately and the common stock and warrants were issued separately. The approximately 1.45 million warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance.
SANUWAVE's PACE Technology Protects Tissue From Ischemia-Reperfusion Injury Common in Microsurgical Procedures
GlobeNewswire - Mon Jul 15, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that pre-clinical results using the Company's patented Pulsed Acoustic Cellular Expression (PACE) technology, which uses focused high-energy acoustic shock waves, were presented by Dr. Maria Siemionow in an oral presentation at the 2013 World Congress of Microsurgery. The results showed that the application of dermaPACE appears to substantially decrease the inflammation and tissue damage that typically occurs when blood flow is interrupted during microsurgical procedures.
SANUWAVE's PACE Data to be Presented at the 2013 World Congress of Microsurgery
GlobeNewswire - Wed Jul 10, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that pre-clinical results using the Company's patented Pulsed Acoustic Cellular Expression (PACE) technology, which uses focused high-energy acoustic shock waves, will be presented by Dr. Maria Siemionow in an oral presentation at the 2013 World Congress of Microsurgery. The international meeting will be held from July 11-14, 2013 in Chicago, Illinois.
SANUWAVE Health Inc to study first diabetic foot ulcer patient in clinical trial of dermaPACE in the US
M2 - Thu Jun 06, 7:01AM CDT
Shock wave technology company SANUWAVE Health Inc (OTC BB:SNWV) reported on Wednesday the start of treatment of the first patient in the supplemental Phase III clinical trial of its dermaPACE device for treating diabetic foot ulcers.
SANUWAVE Health to Hold 2013 Financial Results and Business Update Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Wed Mar 26, 7:30AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the Company will release financial results for the year ended December 31, 2013 after the markets close on March 31, 2014.
SANUWAVE raises gross proceeds of USD10.1m from private placement
M2 - Wed Mar 19, 8:28AM CDT
Regenerative medicine company SANUWAVE Health (OTC BB:SNWV) stated on Tuesday that it has raised gross proceeds of USD10.1m from a private placement led by RA Capital Management.
SANUWAVE Closes $10.1M Private Placement Led by RA Capital Management
GlobeNewswire - Tue Mar 18, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced it has closed a private placement with institutional and select accredited investors raising total gross proceeds of $10.1 million. The financing was led by established life-sciences investor RA Capital Management, LLC, a Boston-based healthcare crossover fund that invests in development-stage private and public drug, medical device, and diagnostic companies and also included existing shareholders. Included in the total is the conversion into equity, under the same terms as the private placement, of $815,000 of convertible notes with existing shareholders, including a member of the management team.
SANUWAVE Announces Agreement for Licensing and Distribution for Gulf Cooperation Council (GCC) Region
GlobeNewswire - Tue Feb 11, 7:30AM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that it has signed an agreement with Wirthlin, a Dentons Innovation Group Partnership (Wirthlin-Dentons), to provide strategic advisory services and to establish a joint venture company that will license its dermaPACE device and create a sales and distribution system for the GCC - defined as the Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Qatar, and Bahrain. The joint venture arrangement expects to have a legal and organizational structure in place in the second quarter of 2014, which enables rollout of SANUWAVE's dermaPACE device in the fourth quarter.
SANUWAVE Provides Update on Patient Enrollment - Over 75% Now Enrolled in Pivotal dermaPACE Clinical Trial
GlobeNewswire - Wed Jan 29, 7:30AM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that it has enrolled over seventy-five percent (75%) of the minimum required patients in the Phase III supplemental clinical trial evaluating the dermaPACE device on patients with diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients; which is on track to occur in the first quarter of 2014.
SANUWAVE Reports Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 7:30AM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported financial results for the three and nine months ended September 30, 2013 and provided a business update. The Company will host a conference call today at 10:00 a.m. Eastern Time.
SANUWAVE to Hold Third Quarter Financial Results Conference Call on Tuesday, November 12
GlobeNewswire - Thu Nov 07, 3:30PM CST
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that the Company will release financial results for the third quarter ended September 30, 2013 prior to the opening of the market on Tuesday, November 12, 2013. The Company will host a conference call on Tuesday, November 12, 2013 at 10:00 a.m. Eastern Time.
SANUWAVE Receives U.S. Patent for New Type of Applicators Used for Shock Wave Technology
GlobeNewswire - Thu Oct 17, 7:31AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled "Extracorporeal Shock Wave Device." The claims of the patent (patent number 8,556,813) relate to a new extracorporeal applicator, which creates significant advantages for certain applications. The patent has a term extending to April 2031.
SANUWAVE Provides Update on Patient Enrollment in Pivotal dermaPACE Clinical Trial
GlobeNewswire - Tue Oct 08, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that it has enrolled fifty percent (50%) of the minimum required patients in the Phase III supplemental clinical trial evaluating the dermaPACE device on patients with diabetic foot ulcers. The clinical trial is designed to enroll a minimum of 90 patients and is on-track for completion in the first quarter of 2014.
SANUWAVE's orthoPACE Medical Device Receives Regulatory Approval in South Korea
GlobeNewswire - Tue Sep 10, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that its orthoPACE device has received official regulatory approval from the South Korean Ministry of Food and Drug Safety (MFDS - South Korea). With this approval, SANUWAVE will begin commercializing orthoPACE in South Korea. The orthoPACE device has been proven safe and effective for the treatment of chronic tendonitis and joint pain in the musculoskeletal system. orthoPACE treatments have been especially effective in treating plantar fasciitis and tendonitis, which commonly require surgery.
OTC Signal Daily Stock Watch - SANUWAVE Health, Inc. (OTCQB: SNWV)
WorldStockWire - Mon Sep 09, 1:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
SANUWAVE Appoints Life Sciences Industry Executive, Alan L. Rubino To Its Board
GlobeNewswire - Wed Sep 04, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced the appointment of Alan L. Rubino to the Company's Board of Directors. Mr. Rubino has more than 30 years of experience at every level of the biopharmaceutical industry, including positions focused on sales and marketing and SEC matters. With this appointment, the Company's Board has four members.
SANUWAVE Reports Second Quarter 2013 Financial Results
GlobeNewswire - Wed Aug 14, 3:30PM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported financial results for the three and six months ended June 30, 2013 and provided a business update. The Company will host a conference call on Thursday, August 15 at 10:00 a.m. Eastern Time.
SANUWAVE to Hold Second Quarter Financial Results Conference Call on Thursday, August 15
GlobeNewswire - Tue Aug 13, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that the Company will release financial results for the second quarter ended June 30, 2013 following the close of the market on Wednesday, August 14, 2013. The Company will hold a conference call on Thursday, August 15 beginning at 10:00 a.m. Eastern time to discuss the second quarter financial results and provide a business update.
SANUWAVE Announces Conversion of All Senior Secured Notes
GlobeNewswire - Mon Aug 05, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that all of the holders of the Company's 18% senior secured convertible promissory notes voluntarily converted all of the outstanding principal and interest of the notes into common stock on July 31, 2013. SANUWAVE had entered into subscription agreements between November 2012 and February 2013 with select accredited investors, most of whom had invested in the Company's previous financing rounds, and issued the aggregate $2.0 million notes in March 2013.
SANUWAVE Health Inc concludes USD1.6m units in public offering
M2 - Fri Jul 26, 6:58AM CDT
Shockwave technology company SANUWAVE Health Inc (OTC BB:SNWV) revealed on Thursday the sale of approximately USD1.6m units in a public offerings at USD0.55 per unit, each unit consist of one share of common stock and a warrant to purchase one-half share of common stock.
SANUWAVE Closes Public Offering
GlobeNewswire - Thu Jul 25, 10:15AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) announced today that it has sold approximately $1.6 million in Units, with each Unit consisting of one share of common stock and a warrant to purchase one-half share of common stock, in a public offering which closed today. The price per Unit is $0.55. The approximately 2.9 million Units separated immediately and the common stock and warrants were issued separately. The approximately 1.45 million warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance.
SANUWAVE's PACE Technology Protects Tissue From Ischemia-Reperfusion Injury Common in Microsurgical Procedures
GlobeNewswire - Mon Jul 15, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that pre-clinical results using the Company's patented Pulsed Acoustic Cellular Expression (PACE) technology, which uses focused high-energy acoustic shock waves, were presented by Dr. Maria Siemionow in an oral presentation at the 2013 World Congress of Microsurgery. The results showed that the application of dermaPACE appears to substantially decrease the inflammation and tissue damage that typically occurs when blood flow is interrupted during microsurgical procedures.
SANUWAVE's PACE Data to be Presented at the 2013 World Congress of Microsurgery
GlobeNewswire - Wed Jul 10, 7:30AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today reported that pre-clinical results using the Company's patented Pulsed Acoustic Cellular Expression (PACE) technology, which uses focused high-energy acoustic shock waves, will be presented by Dr. Maria Siemionow in an oral presentation at the 2013 World Congress of Microsurgery. The international meeting will be held from July 11-14, 2013 in Chicago, Illinois.
SANUWAVE Health Inc to study first diabetic foot ulcer patient in clinical trial of dermaPACE in the US
M2 - Thu Jun 06, 7:01AM CDT
Shock wave technology company SANUWAVE Health Inc (OTC BB:SNWV) reported on Wednesday the start of treatment of the first patient in the supplemental Phase III clinical trial of its dermaPACE device for treating diabetic foot ulcers.
